US pharma giant Gilead uses ‘Double Irish’ tax loophole where to buy illegal steroids online the truth about anabolic steroids and its relation to health and fitness | fit for the soul

Aqemia announces extension of its first collaboration with Sanofi on drug discovery in Oncology

This initial collaboration resulted in promising molecules for an oncology program, for which Sanofi and Aqemia decided to pursue joint efforts, the company claims.

Novartis, tislelizumab, esophageal cancer, chemotherapy, pharma news, health news,
he company also revealed that the incidence of treatment-related adverse events (TRAEs) was similar in both arms. (File)

Aqemia, a next-gen pharmatech company announced on Wednesday that it has entered a new research collaboration with Sanofi. According to the company’s press statement, this new agreement is a follow-up to a Research Collaboration initiated at the end 2020 by Sanofi to bring the unique technologies of Aqemia to the design and discovery of novel molecules in several projects in oncology, a priority therapeutic area for Sanofi.

This initial collaboration resulted in promising molecules for an oncology program, for which Sanofi and Aqemia decided to pursue joint efforts, the company claims.

“Aqemia will take responsibility for the AI-based design of optimized molecules that fulfill several small molecule design goals among which potency and selectivity in a priority project in oncology. Unlike most AI-based technologies that need experimental data to train their algorithms prior to starting the design, Aqemia will tackle the drug discovery project by generating its own data with quantum and statistical physics-based calculations, the company stated.

Moreover, this collaboration includes an undisclosed upfront payment from Sanofi.

“We are really proud of the results obtained in the first Sanofi-Aqemia oncology collaboration and are very excited to continue working together to accelerate important projects in oncology.” He added, “This follow-up of our first collaboration project with Sanofi, a global leader in the Pharmaceutical industry, demonstrates our ability to quickly generate novel potent and selective compounds for a given target, and we can’t wait to scale it up to dozens of drug discovery projects,” Maximilien Levesque, CEO and co-founder of Aqemia, said in a statement.

“We are also extremely excited by the promising results obtained by Aqemia using their proprietary and disruptive technology to design potent inhibitors on given targets. We are eager to prolong our collaboration to speed up our candidate finding process for the sake of patients suffering from cancer,” said Laurent Schio, head of Integrated Drug Discovery of Sanofi France in a statement.

Get live Share Market updates and latest India News and business news on Financial Express. Download Financial Express App for latest business news.

Most Read In Pharma Healthcare
Photos